← Back to Search

Behavioural Intervention

Exercise Training for Sarcopenia

N/A
Waitlist Available
Led By Marcas Bamman
Research Sponsored by Florida Institute for Human and Machine Cognition
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Male or female aged 60 or above
Cognitively capable of providing informed consent
Must not have
Any current infectious disease
Neuromuscular or musculoskeletal disorder that would limit ability to perform the exercise and/or testing bouts
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 23 weeks
Awards & highlights

Summary

This trial aims to study how aging-related declines in physical, mental, and metabolic functions can be improved through exercise. The researchers will investigate the effectiveness of combining endurance and resistance training in older adults to better

Who is the study for?
This trial is for older adults who are experiencing muscle loss and weakness, known as sarcopenia. Participants should be interested in following a combined program of endurance and resistance training according to public health guidelines.
What is being tested?
The study is testing how effective a combination of endurance and resistance exercises can be in improving the health and physical capabilities of older adults with sarcopenia. It aims to understand why people respond differently to exercise.
What are the potential side effects?
Exercise programs may lead to muscle soreness, fatigue, or injury if not performed correctly. However, these side effects are generally mild and can often be managed with proper guidance.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 60 years old or older.
Select...
I am mentally able to understand and agree to the study's procedures.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I do not have any current infections.
Select...
I have a condition that limits my ability to exercise or perform physical tests.
Select...
My lung function is below 80% of what is expected.
Select...
I am taking a high dose of a fat-soluble statin medication.
Select...
I do not drink more than the recommended limit of alcohol.
Select...
I have liver disease or type 2 diabetes based on blood tests.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~23 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 23 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Cardiorespiratory fitness (CRF)
Functional muscle quality (fMQ)
Secondary study objectives
Balance
Body composition
Cognitive performance
+1 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: MitigationExperimental Treatment1 Intervention
Based on these categories of responsiveness, exercise training will be boosted in the three groups that are nonresponsive in one or both outcomes. CRF-/fMQ+ will receive boosted ET, CRF+/fMQ- will receive boosted RT, and CRF-/fMQ- will receive boosting in both. All three of these classifications will also receive education on wearable device data and other free-living recommendations four times during Mitigation
Group II: InterrogationExperimental Treatment1 Intervention
In Interrogation, all participants will exercise train using an exercise prescription that is in accordance with current public health recommendations19. At the end of Phase I participants will be classified into one of the four categories listed in Fig. A: (1) CRF-/fMQ-, 2) CRF-/fMQ+, 3) CRF+/fMQ- and 4) CRF+/fMQ+).

Find a Location

Who is running the clinical trial?

University of FloridaOTHER
1,380 Previous Clinical Trials
762,145 Total Patients Enrolled
7 Trials studying Sarcopenia
244 Patients Enrolled for Sarcopenia
Florida Institute for Human and Machine CognitionLead Sponsor
5 Previous Clinical Trials
288 Total Patients Enrolled
Oklahoma Medical Research FoundationOTHER
22 Previous Clinical Trials
8,082 Total Patients Enrolled
~167 spots leftby Dec 2026